Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Logic says its inflammatory bowel disease drug candidate has shown indications of efficacy at relevant doses in in vivo testing, and is now seeking a partner for its clinical development.
Subscribe to our email newsletter
Gene Logic discovered the new potential therapeutic use for the candidate, GL1001, using its drug repositioning platform, a set of drug evaluation technologies the company uses to assess drug candidates for potential utility across a wide spectrum of disease indications. GL1001 was found to suppress the induction of a key inflammatory mediator both in vivo and in vitro.
The data were also supported by analysis of Gene Logic’s proprietary gene expression database, BioExpress. Gene Logic performed the work under an agreement with Millennium Pharmaceuticals and subsequently acquired certain exclusive rights to GL1001 for commercial development.
Charles Dimmler, III, Gene Logic CEO and president, said: “Our next step will be to secure the right partner to pursue a clinical development strategy for GL1001. At the same time, we are working with our existing drug repositioning partners to discover new uses for their discontinued drug candidates in other therapeutic areas.”